Selenium-binding protein 1 is down-regulated in malignant melanoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Selenium-binding protein 1 (SELENBP1) is downregulated in various cancers and acts as a tumor suppressor.
• SELENBP1 is identified as downregulated in cutaneous melanoma, suggesting a similar tumor suppressor role.

Purpose of the Study:

• To investigate the role of SELENBP1 in melanoma.
• To explore the impact of SELENBP1 re-expression on melanoma cell behavior and the tumor microenvironment.
• To examine the functional interaction between SELENBP1 and Glutathione peroxidase 1 (GPX1) in melanoma.

Main Methods:

• In vitro analysis of SELENBP1 re-expression in human melanoma cell lines.
• Supernatant analysis from transfected melanoma cells on endothelial cells (HMEC).
• Assessment of melanoma cell sensitivity to Vemurafenib treatment.
• Correlation analysis between SELENBP1 and GPX1 mRNA levels.
• Combined re-expression of SELENBP1 and downregulation of GPX1.

Main Results:

• SELENBP1 re-expression did not affect melanoma cell proliferation, migration, or tube formation in vitro.
• Supernatant from SELENBP1-re-expressing melanoma cells suppressed vessel formation in HMEC cells.
• SELENBP1 re-expression altered melanoma cell sensitivity to Vemurafenib.
• Inverse correlation observed between SELENBP1 mRNA and GPX1 expression in melanoma.
• Combined SELENBP1 re-expression and GPX1 downregulation reduced melanoma cell proliferation.

Conclusions:

• SELENBP1 influences the tumor microenvironment in melanoma, particularly affecting angiogenesis.
• SELENBP1's functional activity in melanoma is modulated by its interaction with GPX1.
• Targeting SELENBP1 and GPX1 pathways may offer therapeutic strategies for melanoma.